First In Human Study of CX-2051 in Advanced Solid Tumors
First In Human Study of CX-2051 in Advanced Solid Tumors
Recruiting · NCT06265688 · Registry updated 2026-07-15Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| First In Human Study of CX-2051 in Advanced Solid Tumors | Solid Tumor, Adult | Recruiting | Phase 1 | 2026-07-15 | NCT06265688 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| CytomX Therapeutics | 2 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Carolina BioOncology Institute, PLLC | Huntersville | United States | 1 |
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Montefiore Medical Center | The Bronx | United States | 79 |
| NEXT Virginia | Fairfax | United States | 83 |
| Sarah Cannon Research Institute at HealthOne | Denver | United States | 34 |
| Sarah Cannon Research Institute, LLC | Nashville | United States | 3 |
| START - Dallas/Fort Worth | Fort Worth | United States | 1 |
| START San Antonio LLC | San Antonio | United States | 1 |